Isoxsuprine-d6 hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I045020
  • CAS Number: 2706004-35-3
  • Molecular Formula: C18H18D6ClNO3
  • Molecular Weight: 343.88
  • Purity: ≥95%
Inquiry Now

Isoxsuprine-d6 (hydrochloride) is the deuterium labeled Isoxsuprine hydrochloride. Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].


Catalog Number I045020
CAS Number 2706004-35-3
Synonyms

4-[2-[(1,1,1,2,3,3-hexadeuterio-3-phenoxypropan-2-yl)amino]-1-hydroxypropyl]phenol;hydrochloride

Molecular Formula C18H18D6ClNO3
Purity ≥95%
InChI InChI=1S/C18H23NO3.ClH/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15;/h3-11,13-14,18-21H,12H2,1-2H3;1H/i1D3,12D2,13D;
InChIKey QVPSGVSNYPRFAS-IZPCRJACSA-N
SMILES CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O.Cl
Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]

[2]. Falkay G, et al. Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors. J Perinat Med. 1986;14(2):109-13.
 [Content Brief]

[3]. Kretschy N, et al. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br J Cancer. 2013 Feb 19;108(3):570-8.
 [Content Brief]

[4]. Hill JW, et al. Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One. 2014 May 7;9(5):e96761.
 [Content Brief]

Request a Quote